• CUDC-907: Practical Guidance for Dual PI3K and HDAC Inhibiti

  2026-05-10

  CUDC-907 is a dual PI3K and HDAC inhibitor intended for cell-based in vitro research on cancer signaling, cell cycle, and apoptosis pathways. It should be used only in controlled laboratory settings, with careful adherence to recommended protocols. CUDC-907 is not suitable for diagnostic or therapeutic applications.

• METTL16-SENP3-LTF Axis Drives Ferroptosis Resistance in HCC

  2026-05-09

  Wang et al. (2024) identify the METTL16-SENP3-LTF axis as a key regulator of ferroptosis resistance and tumorigenesis in hepatocellular carcinoma (HCC). Their mechanistic study highlights m6A-dependent regulation of iron metabolism as a promising therapeutic target for sensitizing HCC to ferroptosis.

• Berberrubine Inhibits Thrombosis via Vitamin K Cycle Modulat

  2026-05-08

  This study demonstrates that berberrubine, a principal berberine metabolite, inhibits thrombosis in mice by targeting enzymes of the vitamin K catalytic cycle. Using integrated metabolomics and molecular docking, researchers elucidated a distinct antithrombotic mechanism with reduced bleeding risk, offering a foundation for safer anticoagulant development.

• α2-AR Agonist Hydrogel Modulates Immune Rejection in Osteosa

  2026-05-08

  This study explores the use of α2-adrenergic receptor agonists, delivered via a thermo-sensitive hydrogel, to reduce immune rejection and recurrence in post-surgical osteosarcoma models. Findings indicate that immune modulation—particularly T cell activation—rather than direct cytotoxicity, underpins the observed anti-tumor effects, providing a mechanistic basis for novel immunotherapeutic approaches.

• Verapamil HCl: Applied Workflows in Calcium Channel Blockade

  2026-05-07

  Verapamil HCl stands out as a versatile L-type calcium channel blocker for advanced research on apoptosis, inflammation, and osteoporosis models. This guide translates recent breakthroughs and best-practice protocols into actionable steps for reproducible cell and animal studies.

• Cy5 TSA Fluorescence System Kit: Amplified Sensitivity in IH

  2026-05-07

  The Cy5 TSA Fluorescence System Kit transforms detection of low-abundance biomolecules in immunohistochemistry, immunocytochemistry, and in situ hybridization through 100-fold signal amplification and rapid, covalent Cy5 labeling. This article details optimized workflows, troubleshooting strategies, and key innovations inspired by recent astrocyte transcriptomic breakthroughs.

• Kanamycin Sulfate: Mechanism, Strategy, and Translational Vi

  2026-05-06

  This thought-leadership article explores Kanamycin Sulfate’s mechanistic action as a water-soluble aminoglycoside antibiotic, its pivotal application in modern microbiology and antibiotic resistance research, and strategic guidance for translational scientists. Integrating mechanistic detail, competitive context, and the latest advances in RNA bioprocessing, the article goes beyond protocol guides to map the future of robust, reproducible research.

• VER 155008: HSP 70 Inhibitor Advances Apoptosis Assays in Ca

  2026-05-06

  VER 155008, a potent adenosine-derived HSP 70 inhibitor, empowers researchers to dissect chaperone-mediated pathways and apoptosis in cancer and neurodegeneration models. This guide translates recent mechanistic discoveries into actionable workflows, troubleshooting strategies, and optimized experimental parameters for superior assay performance.

• Freeze-Induced Betaine Loading Boosts LNP mRNA Delivery Effi

  2026-05-05

  This study demonstrates that freezing lipid nanoparticles (LNPs) with the cryoprotectant betaine leads to its incorporation into LNPs through freeze concentration, significantly enhancing mRNA delivery efficacy. The work redefines the role of cryoprotectants, showing they can actively modulate LNP structure and function, opening new avenues for robust mRNA therapeutic development.

• Dual-Action Kinase Inhibitors Modulate p38α Dephosphorylatio

  2026-05-05

  The referenced study reveals that certain kinase inhibitors can promote dephosphorylation of p38α MAP kinase by stabilizing its activation loop in a conformation accessible to phosphatases. This dual-action effect suggests new strategies to enhance the potency and specificity of kinase-targeted therapeutics by leveraging conformational control.

• GANT61: Advanced GLI Inhibitor Workflows for Cancer Research

  2026-05-04

  GANT61 empowers precise inhibition of GLI1/GLI2, enabling researchers to dissect Hedgehog signaling and overcome tumor immune evasion. This guide details experimental workflows, protocol optimizations, and troubleshooting strategies to maximize the impact of GANT61 in translational cancer research.

• Tamsulosin in Applied Urological Research: Protocols & Solut

  2026-05-04

  Leverage Tamsulosin's highly selective α₁A-adrenergic antagonism for advanced urological and smooth muscle research. This guide delivers stepwise protocols, assay-specific troubleshooting, and actionable insights—bridging clinical evidence with bench workflows and highlighting the practical impact of recent biomarker-driven findings.

• Jasplakinolide: Actin Polymerization Inducer for Advanced Ce

  2026-05-03

  Jasplakinolide stands out as a benchmark actin polymerization inducer, enabling precise manipulation of cytoskeletal dynamics in live-cell studies. This guide delivers actionable workflows, troubleshooting insights, and a direct bridge from recent literature to optimized experimental design.

• Anlotinib Hydrochloride: Redefining Multi-Target TKI Strateg

  2026-05-02

  This thought-leadership article explores how Anlotinib hydrochloride, a next-generation multi-target tyrosine kinase inhibitor, is reshaping translational cancer research through mechanistic precision and workflow-focused guidance. By bridging bench-to-bedside priorities, the piece delivers actionable insights for researchers seeking to leverage angiogenesis inhibition, with a strong emphasis on experimental validation, clinical relevance, and future outlook.

• Drug-Sensitized Yeast Enhance mTOR Inhibitor Discovery Sensi

  2026-05-01

  This study introduces an engineered yeast platform with heightened sensitivity for detecting mTOR inhibitors, surpassing the limitations of traditional wild-type models. The system enables rapid, cost-effective screening, robustly distinguishing true TOR pathway inhibitors from unrelated compounds, and sets a new standard for early-stage drug discovery.

15138 records 1/1010 page Next 12345 下5页 Last page